These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 5533446)

  • 1. [Peripheral vasculopathies and some metabolic disorders in the aged. Effectiveness of xanthinol-nicotinate therapy].
    Martinelli V; Montori A; Cappelletti F
    G Gerontol; 1970 Jul; 18(7):661-7. PubMed ID: 5533446
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacological properties and clinical use of xanthinol nicotinate].
    Mashkovskiĭ MD; Iuzhakov SD; Absava GI; Erokhina LG; Lebedeva NV
    Klin Med (Mosk); 1984 Nov; 62(11):30-4. PubMed ID: 6097742
    [No Abstract]   [Full Text] [Related]  

  • 3. [Non-invasive diagnosis and medical therapy of cerebral and/or peripheral atherosclerotic vasculopathies].
    Rezzo R; Stabilini L; Bertoglio C; Ruben G; De Gregori M; Fontana G; Gori A; Petrilli GL
    Clin Ter; 1984 Dec; 111(6):495-511. PubMed ID: 6396028
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy of arteriosclerotic vasculopathies with arterial wall extract].
    Veccia F
    Clin Ter; 1967 Sep; 42(5):429-42. PubMed ID: 5617689
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous heparin anticoagulation in patients with arteriosclerosis and arterial emboli.
    Campbell HC; Hubbard SG; Ernst CB
    Surg Gynecol Obstet; 1980 Jan; 150(1):54-6. PubMed ID: 7350702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of blood circulation disorders with an adenosine-theophylline sodium nicotinate combination].
    Hüdepohl M; Bockelmann R
    Med Klin; 1966 Feb; 61(5):184-6. PubMed ID: 5982907
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombolytic and antiplatelet action of xanthinol nicotinate (Sadamin): possible mechanisms.
    Bieroń K; Swies J; Kostka-Trabka E; Gryglewski RJ
    J Physiol Pharmacol; 1998 Jun; 49(2):241-9. PubMed ID: 9670107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in atherosclerotic dyslipemia induced by the action of xanthinol nicotinate].
    Passanante D; Kabanchik M; Fernández F; Sermukslis B; Smud R; Palermo G
    Prensa Med Argent; 1967 Apr; 54(6):273-9. PubMed ID: 5613947
    [No Abstract]   [Full Text] [Related]  

  • 9. [New method of atherosclerotic macular dystrophies treatment].
    Basinskiĭ SN; Krasnogorskaia VN
    Vestn Oftalmol; 1997; 113(6):17-9. PubMed ID: 9483992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets.
    Liu HQ; Su MX; Di B; Hang TJ; Hu Y; Tian XQ; Zhang YD; Shen JP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Sep; 873(1):20-6. PubMed ID: 18718822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The action of xanthinol nicotinate on the peripheral circulation of the aged].
    Chevat H; Steenhouwer B; Hiltenbrand C; Legrand MF; Graux P
    Angeiologie; 1968; 20(2):33-42. PubMed ID: 5682235
    [No Abstract]   [Full Text] [Related]  

  • 12. [Indications of the use of xanthinol-nicotinate as complementary therapy in medico-surgical treatment of phlebopathies of the lower limbs in the aged].
    Montori A; Martinelli V; Cappelletti F
    G Gerontol; 1970 Jul; 18(7):669-78. PubMed ID: 5533447
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of hyperlipidemia with xanthinol nicotinate as opposed to low fat diet].
    Baumann J; Martschick R
    Med Welt; 1982 Jan; 33(4):139-41. PubMed ID: 7062844
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experience with polysponin therapy of atherosclerosis].
    Milimovka ME; Konovalov MN; Rybnikov NI; Dimant MI
    Vrach Delo; 1971 Jan; (1):63-5. PubMed ID: 5576585
    [No Abstract]   [Full Text] [Related]  

  • 15. [Medical prevention of recurrence in extracranial and peripheral arteriosclerosis].
    Bollinger A
    Verh Dtsch Ges Inn Med; 1981; 87():303-4. PubMed ID: 7331460
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of peripheral arterial insufficiency with inositol nicotinate (Hexanicit)].
    Hentzer E
    Nord Med; 1966 Sep; 76(38):1090-3. PubMed ID: 5918550
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of combined pentosanpolysulfonic ester, xanthinol nicotinate and a rutoside on the serum lipids].
    Sermukslis B; Smud R; Fernandez FJ; Passanante D
    Prensa Med Argent; 1970 Nov; 57(39):1848-51. PubMed ID: 4925318
    [No Abstract]   [Full Text] [Related]  

  • 18. [Variations in fibrinolytic activity and fibrinogen caused by xanthinol nicotinate in cases of diabetes mellitus with peripheral vascular lesions].
    Ipbüker A; Bayer H
    Turk Tip Cemiy Mecm; 1969 Apr; 35(4):236-46. PubMed ID: 5810400
    [No Abstract]   [Full Text] [Related]  

  • 19. [Study of the pharmacodynamic effects of 3-(methyl-oxyethylamino)-2-oxypropyl-theophilline nicotinate on systemic arterial circulation].
    De Gregorio G; Buda A; Fidecaro A
    Boll Soc Ital Biol Sper; 1964 Dec; 40(24):1721-5. PubMed ID: 5877915
    [No Abstract]   [Full Text] [Related]  

  • 20. [The therapy of peripheral circulatory disorders (angiooganopathies) with a blood extract].
    Schirren C; Dietrich K; Biel F
    Hautarzt; 1967 Jun; 18(6):260-4. PubMed ID: 5593511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.